FCCC LOGO Faculty Publications
Benson ABIii , Venook AP , Al-Hawary MM , Arain MA , Chen YJ , Ciombor KK , Cohen SA , Cooper HS , Deming DA , Garrido-Laguna I , Grem JL , Hoffe SE , Hubbard J , Hunt S , Kamel A , Kirilcuk N , Krishnamurthi S , Messersmith WA , Meyerhardt J , Miller ED , Mulcahy MF , Steven Nurkin Md Ms , Overman MJ , Parikh A , Patel H , Pedersen KS , Saltz LB , Schneider C , Shibata D , Skibber JM , Sofocleous CT , Stoffel EM , Stotsky-Himelfarb E , Willett CG , Johnson-Chilla A , Gregory KM , Gurski LA
Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw. 2019 Sep 1;17(9) :1109-1133
Back to previous list
Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than for other related malignancies, including colorectal cancer. Due to the rarity of this disease, few studies have been done to direct optimal treatment, although recent data have shown that SBA responds to treatment differently than colorectal cancer, necessitating a separate approach to treatment. The NCCN Guidelines for Small Bowel Adenocarcinoma were created to establish an evidence-based standard of care for patients with SBA. These guidelines provide recommendations on the workup of suspected SBA, primary treatment options, adjuvant treatment, surveillance, and systemic therapy for metastatic disease. Additionally, principles of imaging and endoscopy, pathologic review, surgery, radiation therapy, and survivorship are described. J Natl Compr Canc Netw. 2019 Sep 1;17(9):1109-1133. doi: 10.6004/jnccn.2019.0043.
Export Date: 1 October 2019